To test this hypothesis, we treated isogenic pairs of murine Ink4a-Arf−/− EGFRvIII glioblastoma lines expressing either IDH1-R132H or wild type IDH1 with the EGFR inhibitor, Gefitinib [41]. Here, CDKN2A is linked to glioblastoma.